MX2010008097A - Acido (-) 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido [1,2-a] pirimidin-9-il) etilamino]benzoico enantiomericamente puro, su uso en terapia medica, y una composicion farmaceutica que lo comprende - 026. - Google Patents

Acido (-) 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido [1,2-a] pirimidin-9-il) etilamino]benzoico enantiomericamente puro, su uso en terapia medica, y una composicion farmaceutica que lo comprende - 026.

Info

Publication number
MX2010008097A
MX2010008097A MX2010008097A MX2010008097A MX2010008097A MX 2010008097 A MX2010008097 A MX 2010008097A MX 2010008097 A MX2010008097 A MX 2010008097A MX 2010008097 A MX2010008097 A MX 2010008097A MX 2010008097 A MX2010008097 A MX 2010008097A
Authority
MX
Mexico
Prior art keywords
pyrido
morpholin
pyrimidin
ethylamino
oxo
Prior art date
Application number
MX2010008097A
Other languages
English (en)
Inventor
Ola Fjellstroem
David Gustafsson
Shaun Jackson
Jan Aa Lundberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40899463&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008097(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010008097A publication Critical patent/MX2010008097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere al ácido (-) 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4H-pirido[1 ,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro o sales farmacéuticamente aceptables del mismo, que está en estado sólido, su uso en terapia médica, una composición farmacéutica que lo comprende, su uso en la preparación de un medicamento para uso en un método para prevenir o tratar enfermedades, y su uso en un método para prevenir o tratar la enfermedad. La presente invención se refiere a un inhibidor selectivo de la fosfoinositido (Pl) 3-quinasa ß y el uso del inhibidor selectivo en e.g. terapia antitrombótica.
MX2010008097A 2008-01-25 2009-01-22 Acido (-) 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido [1,2-a] pirimidin-9-il) etilamino]benzoico enantiomericamente puro, su uso en terapia medica, y una composicion farmaceutica que lo comprende - 026. MX2010008097A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2349808P 2008-01-25 2008-01-25
PCT/SE2009/050065 WO2009093972A1 (en) 2008-01-25 2009-01-22 Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it - 026

Publications (1)

Publication Number Publication Date
MX2010008097A true MX2010008097A (es) 2010-08-04

Family

ID=40899463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008097A MX2010008097A (es) 2008-01-25 2009-01-22 Acido (-) 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido [1,2-a] pirimidin-9-il) etilamino]benzoico enantiomericamente puro, su uso en terapia medica, y una composicion farmaceutica que lo comprende - 026.

Country Status (16)

Country Link
US (1) US20090191177A1 (es)
EP (1) EP2245030A4 (es)
JP (1) JP2011510071A (es)
KR (1) KR20100118977A (es)
CN (1) CN101925601A (es)
AR (1) AR070236A1 (es)
AU (1) AU2009206804A1 (es)
BR (1) BRPI0906805A2 (es)
CA (1) CA2712022A1 (es)
CL (1) CL2009000148A1 (es)
MX (1) MX2010008097A (es)
PE (1) PE20091402A1 (es)
RU (1) RU2010133715A (es)
TW (1) TW200936138A (es)
UY (1) UY31609A1 (es)
WO (1) WO2009093972A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
FR2969613B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
US8815853B2 (en) 2010-12-23 2014-08-26 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
CN104592222B (zh) * 2014-12-26 2016-08-24 苏州明锐医药科技有限公司 抗血小板药物azd6482的制备方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JP2023526058A (ja) * 2020-05-14 2023-06-20 ザ ハート リサーチ インスティテュート リミテッド 抗血小板剤による血栓症及び関連疾患の治療
IL307950A (en) 2021-05-03 2023-12-01 Petra Pharma Corp Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases
AU2022282380A1 (en) 2021-05-27 2023-12-07 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
TW202334137A (zh) * 2021-11-03 2023-09-01 美商薩諾管理公司 Ｐｉ３ｋ抑制劑及治療癌症之方法
WO2023159155A1 (en) * 2022-02-18 2023-08-24 Pivalent Therapeutics, Inc. Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof
WO2023207881A1 (en) * 2022-04-24 2023-11-02 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2024051778A1 (en) * 2022-09-09 2024-03-14 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2024081889A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7998291A (en) * 1990-06-20 1992-01-07 Upjohn Company, The Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
ATE363471T1 (de) * 2000-01-24 2007-06-15 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
CA2495661C (en) * 2002-08-16 2011-06-14 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta

Also Published As

Publication number Publication date
WO2009093972A1 (en) 2009-07-30
JP2011510071A (ja) 2011-03-31
EP2245030A1 (en) 2010-11-03
BRPI0906805A2 (pt) 2015-07-14
PE20091402A1 (es) 2009-10-21
KR20100118977A (ko) 2010-11-08
AU2009206804A1 (en) 2009-07-30
US20090191177A1 (en) 2009-07-30
CL2009000148A1 (es) 2010-10-15
AR070236A1 (es) 2010-03-25
EP2245030A4 (en) 2012-03-21
CA2712022A1 (en) 2009-01-30
TW200936138A (en) 2009-09-01
RU2010133715A (ru) 2012-02-27
CN101925601A (zh) 2010-12-22
UY31609A1 (es) 2009-08-31

Similar Documents

Publication Publication Date Title
MX2010008097A (es) Acido (-) 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido [1,2-a] pirimidin-9-il) etilamino]benzoico enantiomericamente puro, su uso en terapia medica, y una composicion farmaceutica que lo comprende - 026.
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EP3287449A3 (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2009063202A3 (en) Use of crth2 antagonist compounds
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
PL1780197T3 (pl) 5-podstawione-2-fenyloaminobenzamidy jako inhibitory MEK
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2006119300A3 (en) Method of using oxidative reductive potential water solution in dental applications
TW200833663A (en) Therapeutic agents
WO2007119177A3 (en) Modified release formulations and methods of treating inflammatory bowel disease
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
WO2011113507A3 (en) Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal